EGFR and non-small cell lung carcinoma: In a phase I clinical trial assessing the impact of CXCR5-modified CAR T cells targeting EGFR in advanced non-small cell lung carcinoma (NCT05060796), patients exhibited favorable tolerance to the treatment.